Article
Sponsored Content
Scalable rubella production in scale-X™ bioreactor with MRC-5 cells (Nov 2022)
Author(s):
This application note demonstrates the successful transfer, optimization and scale-up of the Rubella vaccine manufacturing process from static flasks to scale-X™ bioreactors.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
